Page last updated: 2024-11-07

beta-aspartylglycine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Beta-aspartylglycine (beta-AG) is a dipeptide formed by the abnormal linkage of aspartic acid and glycine. It is a significant marker for glycation, a process where sugars attach to proteins, and is found in elevated levels in aged tissues and various diseases, such as Alzheimer's disease and diabetes. Research has shown that beta-AG can accumulate in the brain and may contribute to the development of neurodegenerative disorders. Its synthesis is a result of the non-enzymatic Maillard reaction, a chemical process that occurs between reducing sugars and amino groups of proteins. Studies have linked beta-AG to oxidative stress, protein aggregation, and neuronal dysfunction. Due to its potential role in aging and disease pathogenesis, beta-AG is extensively studied as a potential biomarker and therapeutic target.'

beta-aspartylglycine: found in cecum of germ-free & antibiotic-treated mice; RN given refers to (L-beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID99717
CHEMBL ID2074648
CHEBI ID137261
SCHEMBL ID2807629
MeSH IDM0070020

Synonyms (24)

Synonym
3790-52-1
beta-aspartylglycine
CHEBI:137261
l-beta-aspartylglycine
(2s)-2-amino-4-(carboxymethylamino)-4-oxobutanoic acid
AKOS006274882
2mg7g9q44y ,
unii-2mg7g9q44y
nsc 186908
n-l-beta-aspartylglycine
beta-l-aspartylglycine
CHEMBL2074648 ,
SCHEMBL2807629
h-asp(gly-oh)-oh
bdbm50485560
mfcd00063185
(2s)-2-amino-4-(carboxymethylamino)-4-oxo-butanoic acid
l-beta-aspartylglycin
BS-17149
D81930
DTXSID701316273
n4-(carboxymethyl)-l-asparagine
CS-0320181
(s)-2-amino-4-((carboxymethyl)amino)-4-oxobutanoic acid

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Fecal samples were collected before, during, and after therapy from 23 adults who were undergoing treatment of urinary tract infections with pipemidic acid at a dosage of 200 mg orally four times daily for 10 days."( Selective decontamination of the digestive tract by pipemidic acid.
Boerema, HB; Muytjens, HL; van der Ros-van de Repe, J; van der Waaij, D; van Veldhuizen, GL; Welling, GW, 1983
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dipeptideAny molecule that contains two amino-acid residues connected by peptide linkages.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 15 member 2Rattus norvegicus (Norway rat)Ki28,000.00003.00006.47788.5000AID681124
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID681124TP_TRANSPORTER: inhibition of Gly-Sar uptake in PEPT2-expressing LLC-PK1 cells2000Pflugers Archiv : European journal of physiology, Sep, Volume: 440, Issue:5
Structural requirements for determining the substrate affinity of peptide transporters PEPT1 and PEPT2.
AID681125TP_TRANSPORTER: inhibition of Gly-Sar uptake in PEPT1-expressing LLC-PK1 cells2000Pflugers Archiv : European journal of physiology, Sep, Volume: 440, Issue:5
Structural requirements for determining the substrate affinity of peptide transporters PEPT1 and PEPT2.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (27)

TimeframeStudies, This Drug (%)All Drugs %
pre-199020 (74.07)18.7374
1990's1 (3.70)18.2507
2000's6 (22.22)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.72 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index4.12 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (7.41%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (92.59%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]